Trametinib 2mgTablet
Anti-Cancer

Trametinib 2mg

Trametinib Dimethyl Sulfoxide

MEK1/MEK2 inhibitor used in combination with dabrafenib for BRAF V600-mutant melanoma and NSCLC. Manufactured by Natco and Cipla for affordable oncology export.

Strengths

0.5mg / 2mg

Packing

30 tablets/bottle

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Trametinib Dimethyl Sulfoxide 0.5mg / 2mg
Dosage Form
Tablet
Available Strengths
0.5mg / 2mg
Packing
30 tablets/bottle
Route of Administration
Oral, on empty stomach (1 hour before or 2 hours after meal)
Dosage
2mg once daily; used in combination with dabrafenib 150mg twice daily
Indications
Unresectable or metastatic BRAF V600-mutant melanoma, BRAF V600-mutant NSCLC, anaplastic thyroid cancer
Country of Origin
India (WHO-GMP Certified)
Storage
Store at 2-8°C, protect from moisture
Shelf Life
36 months
Side Effects
Rash, diarrhea, peripheral edema, fatigue, pyrexia, nausea, dermatitis acneiform
Precautions
Cardiac monitoring for LVEF decrease; ophthalmologic exams for retinal vein occlusion; dose reduction for severe rash; hemorrhage risk

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Need bulk pricing for Trametinib 2mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote